Display options
Cite
Leunda A, Baldo A, Goossens M, et al. Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations. Vaccines (Basel). 2014;2(2):463-99doi: 10.3390/vaccines2020463.
Leunda, A., Baldo, A., Goossens, M., Huygen, K., Herman, P., & Romano, M. (2014). Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations. Vaccines, 2(2), 463-99. https://doi.org/10.3390/vaccines2020463
Leunda, Amaya, et al. "Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations." Vaccines vol. 2,2 (2014): 463-99. doi: https://doi.org/10.3390/vaccines2020463
Leunda A, Baldo A, Goossens M, Huygen K, Herman P, Romano M. Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations. Vaccines (Basel). 2014 Jun 16;2(2):463-99. doi: 10.3390/vaccines2020463. PMID: 26344627; PMCID: PMC4494264.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2014 Jun 16;2(2):463-99. doi: 10.3390/vaccines2020463.

Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations.

Vaccines

Amaya Leunda, Aline Baldo, Martine Goossens, Kris Huygen, Philippe Herman, Marta Romano

Affiliations

  1. Biosafety and Biotechnology Unit, Scientific Institute of Public Health, 14 Juliette Wytsman Street, Brussels 1050, Belgium. [email protected].
  2. Biosafety and Biotechnology Unit, Scientific Institute of Public Health, 14 Juliette Wytsman Street, Brussels 1050, Belgium. [email protected].
  3. Biosafety and Biotechnology Unit, Scientific Institute of Public Health, 14 Juliette Wytsman Street, Brussels 1050, Belgium. [email protected].
  4. Immunology Unit, Scientific Institute of Public Health, 642 Engeland Street, Brussels 1180, Belgium. [email protected].
  5. Biosafety and Biotechnology Unit, Scientific Institute of Public Health, 14 Juliette Wytsman Street, Brussels 1050, Belgium. [email protected].
  6. Immunology Unit, Scientific Institute of Public Health, 642 Engeland Street, Brussels 1180, Belgium. [email protected].

PMID: 26344627 PMCID: PMC4494264 DOI: 10.3390/vaccines2020463

Abstract

Novel efficient vaccines are needed to control tuberculosis (TB), a major cause of morbidity and mortality worldwide. Several TB vaccine candidates are currently in clinical and preclinical development. They fall into two categories, the one of candidates designed as a replacement of the Bacille Calmette Guérin (BCG) to be administered to infants and the one of sub-unit vaccines designed as booster vaccines. The latter are designed as vaccines that will be administered to individuals already vaccinated with BCG (or in the future with a BCG replacement vaccine). In this review we provide up to date information on novel tuberculosis (TB) vaccines in development focusing on the risk assessment of candidates composed of genetically modified organisms (GMO) which are currently evaluated in clinical trials. Indeed, these vaccines administered to volunteers raise biosafety concerns with respect to human health and the environment that need to be assessed and managed.

Keywords: biosafety; clinical trial; genetically modified organism; risk assessment; tuberculosis; vaccine candidate

References

  1. Virology. 1998 Nov 25;251(2):334-42 - PubMed
  2. J Infect. 2012 Jun;64(6):543-54 - PubMed
  3. Curr Gene Ther. 2013 Dec;13(6):385-94 - PubMed
  4. Nat Rev Immunol. 2004 Jan;4(1):55-66 - PubMed
  5. Virol J. 2013 Dec 05;10:349 - PubMed
  6. Science. 1997 May 30;276(5317):1420-2 - PubMed
  7. Vaccine. 2009 Dec 9;27(52):7442-50 - PubMed
  8. Eur J Immunol. 2010 Jan;40(1):279-90 - PubMed
  9. Sci Transl Med. 2010 Oct 13;2(53):53ra74 - PubMed
  10. PLoS One. 2009;4(5):e5528 - PubMed
  11. PLoS One. 2008;3(10):e3496 - PubMed
  12. J Clin Invest. 2001 Mar;107(5):533-7 - PubMed
  13. EMBO Mol Med. 2011 Apr;3(4):222-34 - PubMed
  14. Mol Microbiol. 2001 Jul;41(1):179-87 - PubMed
  15. J Clin Immunol. 2013 Nov;33(8):1360-75 - PubMed
  16. Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):47-52 - PubMed
  17. PLoS One. 2012;7(6):e39909 - PubMed
  18. Vaccine. 2006 Apr 24;24(17):3408-19 - PubMed
  19. Expert Opin Biol Ther. 2012 Dec;12(12):1601-10 - PubMed
  20. Curr Gene Ther. 2013 Dec;13(6):413-20 - PubMed
  21. FEMS Microbiol Lett. 2003 Feb 28;219(2):261-8 - PubMed
  22. Am J Respir Crit Care Med. 2010 Jun 15;181(12):1407-17 - PubMed
  23. Vaccine. 2007 Jan 2;25(1):14-8 - PubMed
  24. Clin Vaccine Immunol. 2013 May;20(5):663-72 - PubMed
  25. Virol J. 2009 May 12;6:55 - PubMed
  26. Infect Immun. 2011 Jan;79(1):59-66 - PubMed
  27. Vaccines (Basel). 2013 Apr 16;1(2):120-38 - PubMed
  28. Vaccine. 2011 Mar 3;29(11):2100-9 - PubMed
  29. Mol Microbiol. 2011 Sep;81(6):1577-92 - PubMed
  30. Infect Immun. 1987 Jul;55(7):1641-6 - PubMed
  31. Mol Microbiol. 1999 Oct;34(2):257-67 - PubMed
  32. Expert Rev Vaccines. 2009 Jan;8(1):13-24 - PubMed
  33. FEMS Immunol Med Microbiol. 1999 Feb;23(2):165-73 - PubMed
  34. Vaccine. 2013 Feb 18;31(9):1340-8 - PubMed
  35. Curr Gene Ther. 2013 Dec;13(6):421-33 - PubMed
  36. J Immunol. 2003 Aug 1;171(3):1602-9 - PubMed
  37. Vaccine. 2012 Aug 17;30(38):5616-24 - PubMed
  38. Am J Respir Crit Care Med. 2012 Apr 1;185(7):769-78 - PubMed
  39. Vaccine. 2001 Jun 14;19(27):3700-9 - PubMed
  40. Lancet. 1995 Nov 18;346(8986):1339-45 - PubMed
  41. Curr Gene Ther. 2010 Apr;10(2):107-27 - PubMed
  42. BMJ Open. 2011 Nov 14;1(2):e000223 - PubMed
  43. Annu Rev Pathol. 2012;7:353-84 - PubMed
  44. PLoS One. 2013 Oct 18;8(10 ):e77930 - PubMed
  45. Vaccine. 2013 Feb 4;31(7):1026-33 - PubMed
  46. Immunology. 2004 Jul;112(3):461-70 - PubMed
  47. Clin Exp Immunol. 2010 Jul 1;161(1):1-9 - PubMed
  48. Vaccine. 2012 Mar 9;30(12):2098-108 - PubMed
  49. Vaccine. 2009 Jul 16;27(33):4412-23 - PubMed
  50. Vaccine. 2009 Jan 14;27(3):441-5 - PubMed
  51. Scand J Immunol. 2010 Jan;71(1):20-8 - PubMed
  52. Mol Ther. 2009 Jun;17(6):1093-100 - PubMed
  53. J Infect Dis. 2003 Jan 1;187(1):117-23 - PubMed
  54. J Immunol. 1996 Jan 15;156(2):679-84 - PubMed
  55. PLoS One. 2007 Oct 24;2(10):e1052 - PubMed
  56. J Infect Dis. 2011 Jun 15;203(12):1832-43 - PubMed
  57. Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5596-601 - PubMed
  58. Pediatrics. 1995 Jul;96(1 Pt 1):29-35 - PubMed
  59. PLoS One. 2012;7(3):e33555 - PubMed
  60. Vaccine. 2012 Apr 16;30(18):2811-23 - PubMed
  61. Genet Vaccines Ther. 2008 Feb 08;6:5 - PubMed
  62. J Clin Microbiol. 2004 Jan;42(1):212-9 - PubMed
  63. J Gene Med. 2007 Oct;9(10):910-21 - PubMed
  64. Med Etika Bioet. 2002 Spring-Summer;9(1-2):12-9 - PubMed
  65. Clin Exp Immunol. 2005 Jul;141(1):21-8 - PubMed
  66. PLoS One. 2013 Oct 17;8(10):e76442 - PubMed
  67. Lancet. 2013 Mar 23;381(9871):1021-8 - PubMed
  68. J Infect Dis. 2008 Aug 15;198(4):544-52 - PubMed
  69. Vaccine. 2004 Dec 9;23(4):499-506 - PubMed
  70. Lancet. 1996 Jul 6;348(9019):17-24 - PubMed
  71. Microbes Infect. 2008 Feb;10(2):185-97 - PubMed
  72. Vaccine. 2011 Jun 24;29(29-30):4839-47 - PubMed
  73. Vaccine. 2013 Oct 1;31(42):4867-73 - PubMed
  74. PLoS One. 2013 Jun 28;8(6):e67177 - PubMed
  75. J Gen Virol. 2006 Aug;87(Pt 8):2135-43 - PubMed
  76. J Immunol. 1969 Nov;103(5):1089-95 - PubMed
  77. Mol Microbiol. 1996 Apr;20(1):119-26 - PubMed
  78. Am J Respir Crit Care Med. 2009 Apr 15;179(8):724-33 - PubMed
  79. PLoS One. 2012;7(7):e40385 - PubMed
  80. Tuberculosis (Edinb). 2013 Mar;93(2):143-9 - PubMed
  81. Infect Immun. 2002 Oct;70(10):5446-53 - PubMed
  82. Vaccine. 2010 Mar 8;28(11):2259-70 - PubMed
  83. Vaccine. 2012 Mar 30;30(16):2623-32 - PubMed
  84. FEBS J. 2012 Jan;279(1):126-41 - PubMed
  85. J Clin Invest. 2012 Jan;122(1):303-14 - PubMed
  86. Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13853-8 - PubMed
  87. J Clin Invest. 2009 May;119(5):1167-77 - PubMed
  88. Nature. 1999 Nov 4;402(6757):79-83 - PubMed
  89. Vaccine. 2012 Dec 14;30(52):7608-14 - PubMed
  90. Lancet. 2013 Mar 23;381(9871):972-4 - PubMed
  91. Clin Vaccine Immunol. 2011 Jun;18(6):907-13 - PubMed
  92. Infect Immun. 2009 Aug;77(8):3364-73 - PubMed
  93. Sci Transl Med. 2013 Oct 2;5(205):205ra134 - PubMed
  94. JAMA. 2004 May 5;291(17):2086-91 - PubMed
  95. Virology. 1997 Nov 24;238(2):198-211 - PubMed
  96. Vaccine. 2010 Oct 8;28(43):6945-50 - PubMed
  97. PLoS Pathog. 2008 Sep 19;4(9):e1000160 - PubMed
  98. J Immunol. 2004 Nov 15;173(10):6357-65 - PubMed
  99. PLoS One. 2009 Jun 16;4(6):e5934 - PubMed
  100. PLoS One. 2008 Aug 13;3(8):e2921 - PubMed
  101. Int J Tuberc Lung Dis. 1998 Mar;2(3):200-7 - PubMed
  102. JAMA. 1994 Mar 2;271(9):698-702 - PubMed
  103. Int J Tuberc Lung Dis. 2003 Aug;7(8):709 - PubMed
  104. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5299-304 - PubMed
  105. J Clin Invest. 2005 Sep;115(9):2472-9 - PubMed

Publication Types